The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture their views on anticipated prescribing, reimbursement, and market access barriers in relation to current and emerging agents in prostate cancer. Five premium-priced therapies—Zytiga (Johnson & Johnson), Xtandi (Medivation), Provenge (Valeant), Xofigo (Bayer), and Jevtana (Sanofi)—are approved in the United States for prostate cancer, driving the metastatic castrate-resistant prostate cancer (mCRPC) market to become increasingly crowded and competitive. As novel therapies aim to enter this market, sequencing of treatments and gaining optimal reimbursement will be of increasing importance.
Questions Answered in This Report:
- There are five premium-priced therapies approved in the United States for metastatic castrate-resistant prostate cancer (mCRPC). Explore the current prescribing drivers and barriers for these therapies. What role do the prostate cancer therapies play in the treatment of mCRPC in the United States, and in what treatment settings are they prescribed? What factors influence and constrain physician prescribing of therapies? How do physicians expect prescribing to change in the future, and what factors, if any, will drive these changes?
- Explore payer attitudes toward novel emerging therapies for prostate cancer. What factors determine the tier placement of emerging therapies? What factors will influence formulary inclusion of emerging therapies? How do managed care organization (MCO) reimbursement constraints, including tiering and formulary restrictions, impact the potential patient share of emerging drugs?
- Explore clinician and payer attitudes toward the end points of clinical trials that will be critical for securing favorable reimbursement and clinician acceptance of novel therapies. What are physicians’ views on emerging therapies in late-phase development? What clinical benefit do surveyed physicians expect emerging prostate cancer therapies will need to secure favorable reimbursement? What do they believe to be an appropriate clinical trial comparator and primary end point for emerging therapies?
Markets covered: United States.
Primary research: 52 urologists and 50 medical oncologists.
Indication coverage: Prostate cancer.
Emerging therapies: Phase III: 4 drugs.